Published in PLoS One on January 22, 2014
A Novel Small Molecule Inhibitor of Candida albicans Biofilm Formation, Filamentation and Virulence with Low Potential for the Development of Resistance. NPJ Biofilms Microbiomes (2015) 0.85
Competitive Interactions between C. albicans, C. glabrata and C. krusei during Biofilm Formation and Development of Experimental Candidiasis. PLoS One (2015) 0.80
In Vitro and In Vivo Antifungal Activity of Lichochalcone-A against Candida albicans Biofilms. PLoS One (2016) 0.76
Activity of potent and selective host defense peptide mimetics in mouse models of oral candidiasis. Antimicrob Agents Chemother (2014) 0.76
From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms. Microbiol Spectr (2015) 0.76
In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection. Antimicrob Agents Chemother (2017) 0.75
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis (2004) 20.99
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Nonfilamentous C. albicans mutants are avirulent. Cell (1997) 13.83
An amino acid liquid synthetic medium for the development of mycelial and yeast forms of Candida Albicans. Sabouraudia (1975) 11.53
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol (2001) 6.98
Candida biofilms and their role in infection. Trends Microbiol (2003) 5.13
Virulence factors of Candida albicans. Trends Microbiol (2001) 5.01
Amphotericin B: time for a new "gold standard". Clin Infect Dis (2003) 4.01
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med (2012) 4.00
Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res (2001) 3.57
Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis (2003) 3.33
Growth of Candida albicans hyphae. Nat Rev Microbiol (2011) 3.02
Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents (2002) 2.88
Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother (1998) 2.59
Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis (2008) 2.33
Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother (2006) 2.22
Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis (2011) 2.17
Denture stomatitis: a role for Candida biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2004) 2.11
Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol (2012) 2.10
Oral candidiasis. Postgrad Med J (2002) 2.02
Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev (2011) 1.98
Organ-specific innate immune responses in a mouse model of invasive candidiasis. J Innate Immun (2010) 1.94
Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother (2000) 1.93
An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov (2010) 1.78
Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. Antimicrob Agents Chemother (1989) 1.66
Biofilm formation of Candida albicans is variably affected by saliva and dietary sugars. Arch Oral Biol (2004) 1.66
Epidemiology and etiology of denture stomatitis. J Prosthodont (2011) 1.65
Biofilm-forming ability of Candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodeficiency virus infection. J Clin Microbiol (2003) 1.62
Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother (2010) 1.61
Biofilm lifestyle of Candida: a mini review. Oral Dis (2008) 1.48
Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res (2009) 1.48
Candida-associated denture stomatitis. Aetiology and management: a review. Part 2. Oral diseases caused by Candida species. Aust Dent J (1998) 1.28
Rapid flow cytometric susceptibility testing of Candida albicans. J Clin Microbiol (1997) 1.20
Effects of imidazole- and triazole-derivative antifungal compounds on the growth and morphological development of Candida albicans hyphae. J Gen Microbiol (1985) 1.16
Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008. J Hosp Infect (2011) 1.14
A novel murine model of oral candidiasis with local symptoms characteristic of oral thrush. Microbiol Immunol (2003) 1.11
Small-molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans. Antimicrob Agents Chemother (2005) 1.09
Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chem Biol (2004) 1.05
In vitro antifungal activity of hydroxychavicol isolated from Piper betle L. Ann Clin Microbiol Antimicrob (2010) 1.02
In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother (2011) 0.99
Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms. J Antimicrob Chemother (2011) 0.95
Improvement of XTT assay performance for studies involving Candida albicans biofilms. Braz Dent J (2008) 0.94
Comparisons of the effects of fungicidal and fungistatic antifungal agents on the morphogenetic transformation of Candida albicans. J Antimicrob Chemother (1999) 0.94
Small molecule inhibitors of the Candida albicans budded-to-hyphal transition act through multiple signaling pathways. PLoS One (2011) 0.89
Antifungal susceptibility and virulence attributes of bloodstream isolates of Candida from Hong Kong and Finland. Mycopathologia (2011) 0.89
Management of invasive fungal infections: a role for polyenes. J Antimicrob Chemother (2010) 0.88
Persistent Candida albicans colonization and molecular mechanisms of azole resistance in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. J Antimicrob Chemother (2010) 0.88
At what cost echinocandin resistance? J Infect Dis (2011) 0.87
Inhibitors of cellular signalling are cytotoxic or block the budded-to-hyphal transition in the pathogenic yeast Candida albicans. J Med Microbiol (2009) 0.86
Adhesion of oral Candida albicans isolates to denture acrylic following limited exposure to antifungal agents. Arch Oral Biol (1998) 0.83
Protective effects of human saliva on experimental murine oral candidiasis. J Infect Chemother (2004) 0.81
Small-molecule inhibitors of biofilm formation in laboratory and clinical isolates of Candida albicans. J Med Microbiol (2011) 0.81
Rapid screening method for compounds that affect the growth and germination of Candida albicans, using a real-time PCR thermocycler. Appl Environ Microbiol (2011) 0.78
Antibacterial and antifungal drug discovery. Nat Biotechnol (1999) 0.76
Antifungal drug discovery, six new molecules patented after 10 years of feast: why do we need new patented drugs apart from new strategies? Recent Pat Antiinfect Drug Discov (2007) 0.76